1. Home
  2. RGNX
  3. RGNX News

Latest REGENXBIO Inc. (RGNX) News on December 22, 2024

RGNX

Argus Research

5 days ago

RGNX: Rating increased to a HOLD

RGNX

Argus Research

12 days ago

RGNX: Raising target price to $8.00

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
RGNX

PR Newswire

16 days ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

RGNX

Argus Research

19 days ago

RGNX: Lowering target price to $7.00

RGNX

Argus Research

a month ago

RGNX: Rating decreased to a SELL

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
RGNX

Pharmaceutical Technology

a month ago

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy

RGNX

MT Newswires

a month ago

Update: Regenxbio Shares Rise After Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy

RGNX

MT Newswires

a month ago

Sector Update: Health Care Stocks Mixed Premarket Monday

RGNX

MT Newswires

a month ago

Regenxbio Reports Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy - Shares Up Pre-Bell

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
RGNX

PR Newswire

a month ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
RGNX

BioPharma Dive

a month ago

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
RGNX

PR Newswire

a month ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

RGNX

Argus Research

a month ago

RGNX: Raising target price to $11.00

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report
RGNX

Simply Wall St.

a month ago

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations
RGNX

Simply Wall St.

a month ago

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...
RGNX

GuruFocus.com

2 months ago

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
RGNX

Zacks

2 months ago

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

RGNX

Associated Press Finance

2 months ago

Regenxbio: Q3 Earnings Snapshot

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
RGNX

PR Newswire

2 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

RGNX

Argus Research

2 months ago

RGNX: Lowering target price to $9.00

Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings
RGNX

GuruFocus.com

2 months ago

Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

2 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

2 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable
RGNX

Simply Wall St.

2 months ago

The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable

RGNX

MT Newswires

2 months ago

Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
RGNX

PR Newswire

2 months ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
RGNX

PR Newswire

2 months ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc
RGNX

GuruFocus.com

2 months ago

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc

RGNX

Argus Research

2 months ago

RGNX: Rating increased to a HOLD

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
RGNX

PR Newswire

3 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

RGNX

MT Newswires

3 months ago

Regenxbio Names Mitchell Chan CFO

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
RGNX

PR Newswire

3 months ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

RegenxBio touts positive data for rare disease drug RGX-121
RGNX

Pharmaceutical Technology

4 months ago

RegenxBio touts positive data for rare disease drug RGX-121

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
RGNX

PR Newswire

4 months ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

4 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

RGNX

Argus Research

4 months ago

RGNX: What does Argus have to say about RGNX?

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
RGNX

PR Newswire

4 months ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

RGNX

Argus Research

4 months ago

RGNX: Lowering target price to $12.00

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
RGNX

PR Newswire

4 months ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
RGNX

Zacks

5 months ago

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet

REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
RGNX

Simply Wall St.

5 months ago

REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
RGNX

Zacks

5 months ago

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates

RGNX

Associated Press Finance

5 months ago

Regenxbio: Q2 Earnings Snapshot

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

5 months ago

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
RGNX

PR Newswire

5 months ago

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX)
RGNX

GuruFocus.com

5 months ago

Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX)

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks
RGNX

TipRanks

5 months ago

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

5 months ago

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

RGNX

Argus Research

5 months ago

RGNX: What does Argus have to say about RGNX?

RGNX

Argus Research

5 months ago

RGNX: Raising target price to $14.00

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
RGNX

Zacks

5 months ago

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

RGNX

Argus Research

5 months ago

RGNX: What does Argus have to say about RGNX?

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
RGNX

Zacks

5 months ago

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

RGNX

Argus Research

6 months ago

RGNX: Lowering target price to $11.00

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
RGNX

Insider Monkey

6 months ago

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
RGNX

Zacks

6 months ago

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?

RGNX

MT Newswires

6 months ago

Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
RGNX

PR Newswire

6 months ago

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
RGNX

Investor's Business Daily

6 months ago

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
RGNX

Zacks

6 months ago

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

RGNX

MT Newswires

6 months ago

Regenxbio Reports 'Successful' Meeting With FDA For RGX-121

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
RGNX

PR Newswire

6 months ago

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
RGNX

BioPharma Dive

6 months ago

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
RGNX

Zacks

6 months ago

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

RGNX

MT Newswires

6 months ago

Regenxbio Names Curran Simpson President, CEO

Regenxbio CEO to step down after 15 years
RGNX

BioPharma Dive

6 months ago

Regenxbio CEO to step down after 15 years

REGENXBIO Announces Leadership Transition
RGNX

PR Newswire

6 months ago

REGENXBIO Announces Leadership Transition

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RGNX

PR Newswire

7 months ago

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope
RGNX

Simply Wall St.

7 months ago

It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope

RGNX

MT Newswires

7 months ago

HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating

Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results
RGNX

Simply Wall St.

7 months ago

Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results

Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts
RGNX

GuruFocus.com

7 months ago

Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

7 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript
RGNX

Insider Monkey

7 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript

RGNX

MT Newswires

7 months ago

UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating

RGNX

Thomson Reuters StreetEvents

7 months ago

Q1 2024 Regenxbio Inc Earnings Call

RGNX

GuruFocus.com

7 months ago

Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
RGNX

Zacks

7 months ago

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

RGNX

Associated Press Finance

7 months ago

Regenxbio: Q1 Earnings Snapshot

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

7 months ago

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

8 months ago

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
RGNX

PR Newswire

8 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

RGNX

Argus Research

8 months ago

RGNX: Lowering target price to $17.00

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
RGNX

Simply Wall St.

8 months ago

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures

REGENXBIO Sees Positive Results For Macular Degeneration Therapy
RGNX

Exec Edge

9 months ago

REGENXBIO Sees Positive Results For Macular Degeneration Therapy

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
RGNX

PR Newswire

9 months ago

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
RGNX

PR Newswire

9 months ago

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
RGNX

GuruFocus.com

9 months ago

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
RGNX

Motley Fool

9 months ago

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

9 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares
RGNX

GuruFocus.com

10 months ago

Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares

Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates
RGNX

Simply Wall St.

10 months ago

Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
RGNX

PR Newswire

10 months ago

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Announces Proposed Public Offering of Common Stock
RGNX

PR Newswire

10 months ago

REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
RGNX

Zacks

10 months ago

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

Regenxbio data suggest ‘niche’ in Duchenne gene therapy
RGNX

BioPharma Dive

10 months ago

Regenxbio data suggest ‘niche’ in Duchenne gene therapy

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
RGNX

PR Newswire

10 months ago

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
RGNX

PR Newswire

10 months ago

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

RGNX

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Regenxbio Inc Earnings Call

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript
RGNX

Insider Monkey

10 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript

Share on Social Networks: